Dr Shubham Pant discussed the Clinical Question: How to treat KRAS mutant colorectal cancer: the now and the next
Dr Shubham Pant discussed the Clinical Question: How to treat KRAS mutant colorectal cancer: the now and the next
Prof. Shubham Pant is a Hematologist-Oncologist and an Associate Professor of Medicine at University of Texas MD Anderson Cancer Center in Houston. He previously served as the Director of Clinical Trials for the Section of Hematology-Oncology and Associate Director of the Tobacco Settlement Endowment Trust (TSET) Phase 1 program, for the Stephenson Cancer Center in Oklahoma City. Furthermore Prof. Pant was the Oncology Lead of the Clinical Research Disease Site Group for Gastrointestinal Cancers and Clinical Research Disease Site Group Chair for Hepatocellular Cancers at the same institute. Prof. Pant completed his fellowship from the Ohio State University, where he was elected Chief Fellow. He previously served as an elected member at large to the Board of Directors for Cancer and Leukemia Group B (CALGB), was the Site Principal Investigator for CALGB and was a Member of the Board of Trustees for ACTION. Prof. Pant served on the Board of Oklahoma Society of Clinical Oncology. He is a participant in the ASCO Leadership Development Program, Class of 2015-16. His awards include the Golden Pillar Award for Outstanding Patient Service in 2012 and 2014, America’s Top Doctors by Castle Connolly and Oklahoma 40 Under 40 in the Oklahoma Magazine. In 2015, he anchored a health show on CNN-IBN India titled: ‘Let’s Talk Health’.
Consulting or advisory Role: Zymeworks, Ipsen, Novartis, Janssen, AskGene Pharma, BPGBio, Jazz, AstraZeneca, Boehringer Ingelheim, USWorldmeds, Nihon Medi-Physics Co, Ltd, Alligator Bioscience, Theriva Biosciences.
Research funding (funding to institution): Mirati Therapeutics, Lilly, Xencor, Novartis, Bristol-Myers Squibb, Astellas, Framewave, 4D Pharma, Boehringer Ingelheim, NGM Pharmaceuticals, Janssen, Arcus, Elicio, Biontech, Ipsen, Zymeworks, Pfizer, ImmunoMET, Immuneering, Amal Therapeutics.
10 years of independent medical education in GI oncology
Journey through a patient case from testing and diagnosis to treatment and AE management
Looking beyond the obvious mutations in non-small-cell lung cancer
Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer
Maximising outcomes for patients with advanced CRC
Make decisions for your patient at two key stages in their journey